New developments in endocervical glandular lesions

Histopathology

Volumn 62, Issue 1, 2013, Pages 138-160

  McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Adenocarcinoma; Cervix; Endocervix; Immunohistochemistry

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD56 ANTIGEN; CD99 ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; ESTROGEN RECEPTOR; PROTEIN P16; PROTEIN P63; SYNAPTOPHYSIN; VIMENTIN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CERVICAL GLANDULAR INTRAEPITHELIAL NEOPLASIA; DISEASE ASSOCIATION; ECTOPIC TISSUE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; MERKEL CELL; MESONEPHROMA; METASTASIS; NEUROFILAMENT; PRECANCER; PRIORITY JOURNAL; REVIEW; STRATIFIED MUCIN PRODUCING INTRAEPITHELIAL LESION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX TUMOR; UTERINE ENDOCERVIX; WART VIRUS; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; CARCINOMA, ENDOMETRIOID; CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PROGNOSIS; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84871162961     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12012     Document Type: Review

References (118)

1. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001; 357; 1490-1493.
2. Hemminki K, Li X, Vaittinen P. Time trends in the incidence of cervical and other genital squamous cell carcinomas and adenocarcinomas in Sweden, 1958-1996. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002; 101; 64-69.
3. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24year population-based study. Gynecol. Oncol. 2000; 78; 97-105.
4. Bulk S, Visser O, Rozendaal L et al. Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int. J. Cancer 2005; 113; 1005-1009.
5. Friedell GH, McKay DG. Adenocarcinoma in situ of the endocervix. Cancer 1953; 6; 887-897.
6. Tavassoli FA, Devilee P eds. World Health Organization classification of tumours: pathology and genetics. Tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
7. Fox H, Buckley CH, Al-Nafussi AI, et al.Histopathology reporting in cervical screening. NHS Cervical Screening Programme (NHSCSP), Sheffield, England. Publication No. 10; April 1999.
8. Brown LJ, Wells M. Cervical glandular atypia associated with squamous intraepithelial neoplasia: a premalignant lesion. J. Clin. Pathol. 1986; 39; 22-28.
9. McCluggage WG. Endocervical glandular lesions: controversial aspects and ancillary techniques. J. Clin. Pathol. 2003; 56; 164-173.
10. Gloor E, Hurlmann J. Cervical intraepithelial glandular neoplasia (adenocarcinoma in situ and glandular dysplasia). Cancer 1986; 58; 1272-1280.
11. Goldstein NS, Ahmad E, Hussain M, Hankin RC, Perez-Reyes N. Endocervical glandular atypia: does a preneoplastic lesion of adenocarcinoma in situ exist?Am. J. Clin. Pathol. 1998; 110; 200-209.
12. Ioffe OB, Sagae S, Moritani S, Dahmoush L, Chen TT, Silverberg SG. Symposium part 3. Should pathologists diagnose endocervical preneoplastic lesions 'less than' adenocarcinoma in situ? Counterpoint. Int. J. Gynecol. Pathol. 2002; 22; 18-21.
13. Lee KR. Symposium part 3. Should pathologists diagnose endocervical preneoplastic lesions 'less than' adenocarcinoma in situ? Counterpoint. Int. J. Gynecol. Pathol. 2002; 22; 22-24.
14. Kurian K, Al-Nafussi A. Relation of cervical glandular intraepithelial neoplasia to microinvasive and invasive adenocarcinoma of the uterine cervix: a study of 121 cases. J. Clin. Pathol. 1999; 52; 112-117.
15. Lee KR, Sun D, Crum CP. Endocervical intraepithelial glandular atypia (dysplasia): a histopathologic, human papillomavirus, and MIB1 analysis of 25 cases. Hum. Pathol. 2000; 31; 656-664.
16. Jaworski RC, Pacey NF, Greenberg ML et al. The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri. Cancer 1988; 61; 1171-1181.
17. McCluggage WG, Shah R, Connolly LE, McBride HA. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial immunophenotype with consistent expression of CDX2. Int. J. Gynecol. Pathol. 2008; 27; 92-100.
18. Nicolae A, Goyenaga P, McCluggage WG, Preda O, Nogales FF. Endometrial intestinal metaplasia: a report of two cases, including one associated with cervical intestinal and pyloric metaplasia. Int. J. Gynecol. Pathol. 2011; 30; 492-496.
19. Schlesinger C, Silverberg SG. Endocervical adenocarcinoma in situ of tubal type and its relation to atypical tubal metaplasia. Int. J. Gynecol. Pathol. 1999; 73; 305-311.
20. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002; 41; 313-321.
21. Park JJ, Sun D, Quade BJ et al. Stratified mucin producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia?Am. J. Surg. Pathol. 2000; 24; 1414-1419.
22. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 2009; 105; 103-104.
23. Creasman WT. New gynecologic cancer staging. Gynecol. Oncol. 1995; 58; 198-202.
24. Hirschowitz L, Ganesan R, Singh N, McCluggage WG. Dataset for the histological reporting of cervical neoplasia. R. Coll. Pathol. 2011.
25. McCluggage WG. Ten problematic issues identified by pathology review for multidisciplinary gynaecological oncology meetings. J. Clin. Pathol. 2012; 65; 293-301.
26. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002; 41; 185-207.
27. Rollason TP, Cullimore J, Bradgate MG. A suggested columnar cell morphological equivalent of squamous carcinoma in situ with early stromal invasion. Int. J. Gynecol. Pathol. 1989; 8; 230-236.
28. Wheeler DT, Kurman RJ. The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma. Int. J. Gynecol. Pathol. 2005; 24; 125-30.
29. Al-Kalbani M, McVeigh G, Nagar H, McCluggage WG. Do FIGO stage 1A and small (≤2cm) 1B1 adenocarcinomas have a good prognosis and warrant less radical surgery?Int. J. Gynecol. Cancer 2011; 22; 291-295.
30. Baalbergen A, Smedts F, Helmerhorst TJM. Conservative therapy in microinvasive adenocarcinoma of the cervix is justified. An analysis of 59 cases and a review of the literature. Int. J. Gynecol. Cancer 2011; 21; 1640-1645.
31. Ostor AG. Early invasive adenocarcinoma of the uterine cervix. Int. J. Gynecol. Pathol. 2000; 19; 29-38.
32. Ceballos KM, Shaw D, Daya D. Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis. Am. J. Surg. Pathol. 2006; 30; 370-374.
33. Reynolds EA, Tierney K, Keeney G et al. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet. Gynecol. 2010; 116; 1150-1157.
34. Balega J, Michael H, Hurteau J et al. The risk of nodal metastasis in early adenocarcinoma of the uterine cervix. Int. J. Gynecol. Cancer 2004; 14; 104-109.
35. Smith HO, Qualls CR, Romero AA et al. Is there a difference in survival for 1A1 and 1A2 adenocarcinoma of the uterine cervix?Gynecol. Oncol. 2002; 85; 229-241.
36. Yahata T, Nishino K, Kashima K et al. Conservative treatment of stage 1A1 adenocarcinoma of the uterine cervix with a long-term follow-up. Int. J. Gynecol. Cancer 2010; 20; 1063-1066.
37. Houghton O, Jamison J, Wilson R, Carson J, McCluggage WG. p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infectionHistopathology 2010; 57; 342-350.
38. Park KJ, Kiyokawa T, Soslow RA et al. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Am. J. Surg. Pathol. 2011; 35; 633-646.
39. Pirog EC, Kleter B, Olgac S et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am. J. Pathol. 2000; 157; 1055-1062.
40. Hee JA, Kim KR, Kim IS. Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod. Pathol. 2005; 18; 528-534.
41. Duggan MA, McGregor SE, Benoit JL et al. The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis. Hum. Pathol. 1995; 26; 319-325.
42. Tenti P, Romagnoli S, Silini E et al. Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Am. J. Clin. Pathol. 1996; 106; 52-56.
43. Skylderg BM, Murray E, Lambkin H et al. Adenocarcinoma of the uterine cervix in Ireland and Sweden: human papillomavirus infection and biologic alterations. Mod. Pathol. 1999; 12; 675-682.
44. Kojima A, Mikami Y, Sudo T et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am. J. Surg. Pathol. 2007; 31; 664-672.
45. Kusanagi Y, Kogima A, Mikami Y et al. Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am. J. Pathol. 2010; 177; 2169-2175.
46. McCluggage WG, Harley I, Houghton JP, Geyer FC, McKay A, Reis-Filho JS. Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in patient with Peutz-Jeghers syndrome. J. Clin. Pathol. 2010; 63; 935-941.
47. Karamurzin Y, Parkash V, Kiyokawa R, Soslow RA, Park KJ. Immunohistochemical profile of gastric type endocervical adenocarcinoma, including HER2/neu status. Mod. Pathol. 2012; 25(Suppl. 2); 1172A.
48. Karamurzin Y, Parkash V, Kiyokawa R, Soslow RA, Park KJ. Gastric type endocervical adenocarcinoma - an aggressive histologic subtype. Mod. Pathol. 2012; 25(Suppl. 2); 1171A.
49. Clement PB, Young RH, Keh P, Ostor AG, Scully RE. Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am. J. Surg. Pathol. 1995; 19; 1158-1171.
50. Bague S, Rodriquez IM, Prat J. Malignant mesonephric tumors of the female genital tract. A clinicopathologic study of 9 cases. Am. J. Surg. Pathol. 2004; 28; 601-607.
51. Silver SA, Devouassoux-Shisheboran M, Mezzetti TP, Tavassoli FA. Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings. Am. J. Surg. Pathol. 2001; 25; 379-387.
52. Kenny SL, McBride HA, Jamison J, McCluggage WG. Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV negative neoplasms which are commonly PAX8, CA125 and HMGA2 positive and which may be immunoreactive with TTF1 and hepatocyte nuclear factor 1 beta. Am. J. Surg. Pathol. 2012; 36; 799-807.
53. Mansor S, McCluggage WG. Cervical adenocarcinoma resembling breast lobular carcinoma: a hitherto undescribed variant of primary cervical adenocarcinoma. Int. J. Gynecol. Pathol. 2010; 29; 594-599.
54. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD. Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. Am. J. Surg. Pathol. 2009; 33; 835-843.
55. Lemoine NR, Hall PA. Epithelial tumors metastatic to the uterine cervix. A study of 33 cases and review of the literature. Cancer 1986; 57; 2002-2005.
56. McCluggage WG, Hurrell DP, Kennedy K. Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am. J. Surg. Pathol. 2010; 34; 735-741.
57. Ronnett BM, Yemelyanova AV, Vang R et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am. J. Surg. Pathol. 2008; 32; 1835-1853.
58. Chang MC, Nevadunsky NS, Viswanathan AN, Crum CP, Feltmate CM. Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int. J. Gynecol. Pathol. 2010; 29; 88-92.
59. Hayashi I, Tsuda H, Shimoda T. Reappraisal of orthodox histochemistry for the diagnosis of minimal deviation adenocarcinoma of the cervix. Am. J. Surg. Pathol. 2000; 24; 559-562.
60. Ichimura T, Koizumi T, Tateiwa H et al. Immunohistochemical expression of gastric mucin and p53 in minimal deviation adenocarcinoma of the uterine cervix. Int. J. Gynecol. Pathol. 2001; 20; 220-226.
61. Toki T, Shiozawa T, Hosaka N, Ishii K, Nikaido T, Fujii S. Minimal deviation adenocarcinoma of the uterine cervix has abnormal expression of sex steroid receptors, CA125, and gastric mucin. Int. J. Gynecol. Pathol. 1997; 16; 111-116.
62. Utsugi K, Hirai Y, Takeshima N et al. Utility of the monoclonal antibody HIK1083 in the diagnosis of adenoma malignum of the uterine cervix. Gynecol. Oncol. 1999; 75; 345-348.
63. Kondo T, Hashi A, Murata SI et al. Gastric mucin is expressed in a subset of endocervical tunnel clusters: type A tunnel clusters of gastric phenotype. Histopathology 2007; 50; 843-850.
64. Nucci MR, Clement PB, Young RH. Lobular endocervical glandular hyperplasia, not otherwise specified: a clinicopathologic analysis of thirteen cases of a distinctive pseudoneoplastic lesion and comparison with fourteen cases of adenoma malignum. Am. J. Surg. Pathol. 1999; 23; 886-891.
65. Mikami Y, Hata S, Melamed J et al. Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype. Histopathology 2001; 39; 364-372.
66. Mikami Y, Kiyokawa T, Moriya T, Sasano H. Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology 2005; 46; 130-136.
67. Mikami Y, Kiyokawa T, Hata S et al. Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and 'adenoma malignum'. Mod. Pathol. 2004; 17; 962-972.
68. Nara M, Hashi A, Murata S et al. Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol. Oncol. 2007; 106; 289-298.
69. Kawauchi S, Ksuda T, Liu XO et al. Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma? A comparative molecular-genetic and immunohistochemical studyAm. J. Surg. Pathol. 2008; 32; 1807-1815.
70. Mikami Y, Kiyokawa T, Sasajima Y et al. Reapprasial of synchronous and multifocal mucinous lesions of the female genital tract: a close association with gastric metaplasia. Histopathology 2009; 54; 184-191.
71. Seidman JD. Mucinous lesions of the fallopian tube. Am. J. Surg. Pathol. 1994; 18; 1205-1212.
72. Young RH, Scully RE. Mucinous tumors of the ovary associated with mucinous adenocarcinomas of the cervix. A clinicopathologic analysis of 16 cases. Int. J. Gynecol. Pathol. 1988; 7; 99-111.
73. Nucci MR, Ferry JA, Young RH. Ectopic prostatic tissue in the uterine cervix: a report of four cases and review of ectopic prostatic tissue. Am. J. Surg. Pathol. 2000; 24; 1224-1230.
74. McCluggage WG, Ganesan R, Hirschowitz L, Miller K, Rollason TP. Ectopic prostatic tissue in the uterine cervix and vagina: report of a series with a detailed immunohistochemical analysis. Am. J. Surg. Pathol. 2006; 30; 209-215.
75. McCluggage WG, Young RH. Tubulo-squamous polyp: a report of ten cases of a distinctive hitherto uncharacterized vaginal polyp. Am. J. Surg. Pathol. 2007; 31; 1013-1019.
76. Kelly P, McBride HA, Kennedy K, Connolly LE, McCluggage WG. Misplaced Skene's glands: glandular elements in the lower female genital tract that are variably immunoreactive with prostate markers and that encompass vaginal tubulosquamous polyp and cervical ectopic prostatic tissue. Int. J. Gynecol. Pathol. 2011; 30; 605-612.
77. Kazakov DV, Stewart CJ, Kacerovska D et al. Prostatic-type tissue in the lower female genital tract: a morphologic spectrum, including vaginal tubulosquamous polyp, adenomyomatous hyperplasia of paraurethral Skene glands (female prostate), and ectopic lesion in the vulva. Am. J. Surg. Pathol. 2010; 34; 950-955.
78. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am. J. Surg. Pathol. 2009; 33; 914-924.
79. McCluggage WG. Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology 2007; 39; 97-111.
80. Kong CS, Beck AH, Longacre TA. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am. J. Surg. Pathol. 2010; 34; 915-926.
81. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int. J. Gynecol. Pathol. 2002; 21; 4-10.
82. McCluggage WG, Sumathi VP, McBride HA, Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int. J. Gynecol. Pathol. 2002; 21; 11-15.
83. Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns. Am. J. Surg. Pathol. 1986; 10; 568-576.
84. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int. J. Gynecol. Pathol. 2003; 22; 231-235.
85. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG. Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int. J. Surg. Pathol. 2010; 18; 138-143.
86. Tambouret R, Clement PB, Young RH. Endometrial endometrioid adenocarcinoma with a deceptive pattern of spread to the uterine cervix: a manifestation of stage IIb endometrial carcinoma liable to be misinterpreted as an independent carcinoma or a benign lesion. Am. J. Surg. Pathol. 2003; 27; 1080-1088.
87. Yemelyanova A, Ji H, Shih I, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am. J. Surg. Pathol. 2009; 33; 1504-1514.
88. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int. J. Gynecol. Pathol. 2007; 26; 328-333.
89. Saad RS, Mashhour M, Noftech-Moses S et al. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin. Int. J. Gynecol. Pathol. 2012; 31; 57-65.
90. Hirschowitz L, Ganesan R, McCluggage WG. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology 2009; 55; 478-482.
91. McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology 2011; 59; 786-788.
92. Kamoi S, Al Juboury ML, Akin MR et al. Immunohistochemical staining in the distinction between endometrial and endocervical adenocarcinomas: another viewpoint. Int. J. Gynecol. Pathol. 2002; 21; 217-223.
93. Westin SN, Lacour RA, Urbauer DL et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J. Clin. Oncol. 2008; 26; 5965-5971.
94. Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women 40years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am. J. Surg. Pathol. 2009; 33; 1869-1877.
95. Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am. J. Surg. Pathol. 1997; 21; 905-914.
96. Albores-Saavedra J, Martinez-Benitez B, Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favourable prognosis. Int. J. Gynecol. Pathol. 2008; 27; 333-339.
97. Sato Y, Shimamoto T, Amada S et al. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int. J. Gynecol. Pathol. 2003; 22; 226-230.
98. Conner MG, Richter H, Moran CA et al. Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann. Diagn. Pathol. 2002; 6; 345-348.
99. Grayson W, Rhemtula HA, Taylor LF et al. Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases. J. Clin. Pathol. 2002; 55; 108-114.
100. Ishida GM, Kato N, Hayasaka T et al. Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical and molecular genetic study. Int. J. Gynecol. Pathol. 2004; 23; 366-372.
101. McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and p63. Am. J. Surg. Pathol. 2010; 34; 525-532.
102. Li JD, Zhuang Y, Li YF et al. A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases. J. Clin. Pathol. 2011; 64; 1102-1107.
103. O'Neill CJ, McCluggage WG. P16 expression in the female genital tract and its value in diagnosis. Adv. Anat. Pathol. 2006; 13; 8-15.
104. Wang TY, Chen BF, Yang YC et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum. Pathol. 2001; 32; 479-486.
105. Houghton O, McCluggage WG. The expression and diagnostic utility of p63 in the female genital tract. Adv. Anat. Pathol. 2009; 16; 316-321.
106. Pulitzer MP, Amin BD, Busam KJ. Merkel cell carcinoma: review. Adv. Anat. Pathol. 2009; 16; 135-144.
107. Chan JK, Suster S, Wenig BM et al. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am. J. Surg. Pathol. 1997; 21; 226-234.
108. Nagao T, Gaffey TA, Olsen KD et al. Small cell carcinoma of the major salivary glands: clinicopathologic study with emphasis on cytokeratin 20 immunoreactivity and clinical outcome. Am. J. Surg. Pathol. 2004; 28; 762-770.
109. Harmse JL, Carey FA, Baird AR et al. Merkel cells in the human oesophagus. J. Pathol. 1989; 189; 176-179.
110. Coleman NM, Smith-Zagone MJ, Tanyi J et al. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. Am. J. Surg. Pathol. 2006; 30; 405-410.
111. Schmidt U, Müller U, Metz KA, Leder LD. Cytokeratin and neurofilament protein staining in Merkel cell carcinoma of the small cell type and small cell carcinoma of the lung. Am. J. Dermatopathol. 1998; 20; 346-351.
112. Shah IA, Netto D, Schlageter MO, Muth C, Fox I, Manne RK. Neurofilament immunoreactivity in Merkel-cell tumors: a differentiating feature from small-cell carcinoma. Mod. Pathol. 1993; 6; 3-9.
113. Duncavage EJ, Le BM, Wang D, Pfeifer JD. Merkel cell polyomavirus: a specific marker for Merkel cell carcinoma in histologically similar tumors. Am. J. Surg. Pathol. 2009; 33; 1771-1777.
114. Busam KJ, Jungbluth AA, Rekthman N et al. Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas. Am. J. Surg. Pathol. 2009; 33; 1378-1385.
115. Malpica A, Moran CA. Primitive neuroectodermal tumor of the cervix: a clinicopathologic and immunohistochemical study of two cases. Ann. Diagn. Pathol. 2002; 6; 281-287.
116. McCluggage WG, Sumathi VP, Nucci MR et al. Ewing family of tumours involving the vulva and vagina: report of a series of four cases. J. Clin. Pathol. 2007; 60; 674-680.
117. Collini P, Sampietro G, Bertulli R et al. Cytokeratin immunoreactivity in 41 cases of ES/pNET confirmed by molecular diagnostic studies. Am. J. Surg. Pathol. 2001; 25; 273-274.
118. Pagani A, Macri L, Rosulen A et al. Neuroendocrine differentiation in Ewing's sarcomas and primitive neuroectodermal tumors revealed by reverse transcriptase-polymerase chain reaction of the chromogranin mRNA. Diagn. Mol. Pathol. 1998; 7; 36-43.